Retrophin announced the appointment of Noah L. Rosenberg, M.D., as chief medical officer, where he will oversee the clinical development of Retrophin’s product pipeline.    Dr. Rosenberg brings to Retrophin more than 20 years of clinical and therapeutic development experience, including advancing several mid- and late-stage programs across therapeutic areas through to commercialization.   “Noah’s expertise and career-long focus on therapeutic innovation and patient quality of care ...